Meds & supplements › Carmustine
Medicine
Carmustine for injection, USP is indicated as palliative therapy as a single agent or in established combination therapy in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
GLIADEL Wafer is indicated for the treatment of patients with:
The following serious adverse reactions are discussed elsewhere in the labeling:
None.
Store GLIADEL Wafer at or below -20ºC (-4ºF).
Do not keep unopened foil pouches at ambient room temperature for more than six hours at a time for up to three cycles within a 30-day period.
GLIADEL Wafer is a cytotoxic drug and special handling and disposal procedures should be considered. 1
sofidex [Internet]. Daloreum; c2026. Carmustine; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/carmustine
sofidex. (2026, August 2). Carmustine. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/carmustine
Carmustine. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/carmustine
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.